Virtus ETF Advisers LLC Jounce Therapeutics, Inc. Transaction History

Virtus ETF Advisers LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 10, 2018	SELL	$7.27 - $21.88 $427,963 - $1.29 Million	-58,867 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$13.4 - $28.4 $427,714 - $906,499	31,919 Added 118.45%	58,867 $1.32 Million
Q4 2017 Feb 14, 2018	BUY	$12.52 - $17.82 $83,258 - $118,503	6,650 Added 32.76%	26,948 $344,000
Q3 2017 Nov 14, 2017	BUY	$11.17 - $16.99 $20,731 - $31,533	1,856 Added 10.06%	20,298 $316,000
Q2 2017 Aug 14, 2017	BUY	N/A	18,442	18,442 $259,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.